Gong Xiaoqing, Tan Shuoyan, Wang Lingling, Tian Yanan, Zhang Qianqian, Tong Henry H Y, Yao Xiaojun, Liu Huanxiang
Faculty of Applied Sciences, Macao Polytechnic University, Macao 999078, China.
State Key Laboratory of Chinese Medicine Modernization, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China.
ACS Chem Neurosci. 2025 Aug 6;16(15):2800-2811. doi: 10.1021/acschemneuro.5c00054. Epub 2025 Jul 10.
Leucine-rich repeat kinase 2 (LRRK2) is one of the most promising targets for the treatment of Parkinson's Disease. The activation of LRRK2 is regulated by the conserved Asp-Tyr-Gly (DYG) motif of the activation loop. Understanding the flipping process of the DYG motif from active to inactive is crucial for the regulation of LRRK2 kinase catalytic activity. Typically, type I inhibitors stabilize LRRK2 in the active conformation, while type II inhibitors favor the inactive state. To investigate the DYG-flipping mechanism, we performed well-tempered metadynamics simulations on LRRK2 in three distinct states: (1) the apo (ligand-free) state, (2) the type I inhibitor-bound state (DNL201), and (3) the type II inhibitor-bound state (rebastinib). The two-dimensional free energy landscape of DYG flipping in LRRK2 revealed transition pathways between the active ("DYG-in") and inactive ("DYG-out") states. Two distinct pathways were identified, which were differentiated by the orientation of Y2018. In the apo system, the DYG motif undergoes an upward flipping motion. Notably, type I inhibitor DNL201 stabilizes LRRK2 in the DYG-in active conformation, whereas type II inhibitor rebastinib promotes a downward flip into the DYG-out inactive state. These findings elucidate the conformational dynamics of LRRK2 in both unbound and ligand-regulated states as well as the mechanistic details of DYG motif flipping. Our study provides critical structural insights for targeted inhibition of LRRK2 kinase activity.
富含亮氨酸重复激酶2(LRRK2)是治疗帕金森病最有前景的靶点之一。LRRK2的激活受激活环保守的天冬氨酸-酪氨酸-甘氨酸(DYG)基序调控。了解DYG基序从活性状态到非活性状态的翻转过程对于LRRK2激酶催化活性的调节至关重要。通常,I型抑制剂使LRRK2稳定在活性构象,而II型抑制剂则有利于非活性状态。为了研究DYG翻转机制,我们对处于三种不同状态的LRRK2进行了温度加速分子动力学模拟:(1)无配体(apo)状态,(2)I型抑制剂结合状态(DNL201),以及(3)II型抑制剂结合状态(瑞巴替尼)。LRRK2中DYG翻转的二维自由能景观揭示了活性(“DYG在位”)和非活性(“DYG不在位”)状态之间的转变途径。确定了两条不同的途径,它们由Y2018的取向区分。在无配体系统中,DYG基序经历向上翻转运动。值得注意的是,I型抑制剂DNL201使LRRK2稳定在DYG在位的活性构象,而II型抑制剂瑞巴替尼促进向下翻转进入DYG不在位的非活性状态。这些发现阐明了LRRK2在未结合状态和配体调节状态下的构象动力学以及DYG基序翻转的机制细节。我们的研究为靶向抑制LRRK2激酶活性提供了关键的结构见解。